Haemonetics (HAE) Capital Expenditures (2009 - 2026)

Haemonetics has reported Capital Expenditures for 18 years, with the latest figure at $17.7 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 12.9% year-over-year to $17.7 million; the trailing twelve-month figure through Mar 2026 stood at $32.8 million (down 16.54% YoY), and the FY2026 full-year result was $32.8 million, down 16.54% from the prior year.
• Capital Expenditures for Q1 2026 stood at $17.7 million, up from $6.3 million in the prior quarter.
• The five-year high for Capital Expenditures was $93.1 million in Q2 2023, with the low at $3.8 million in Q2 2025.
• Average Capital Expenditures over 5 years is $20.2 million, with a median of $12.0 million recorded in 2023.
• Year-over-year, Capital Expenditures soared 226.65% in 2022 and plunged 92.82% in 2024.
• Tracing HAE's Capital Expenditures over 5 years: stood at $16.8 million in 2022, then declined by 13.07% to $14.6 million in 2023, then plunged by 41.65% to $8.5 million in 2024, then decreased by 25.71% to $6.3 million in 2025, then soared by 178.17% to $17.7 million in 2026.
• The last three Capital Expenditures figures came in at $17.7 million (Q1 2026), $6.3 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.

Peer Comparison